Pacira BioSciences (PCRX) Retained Earnings (2010 - 2026)

Pacira BioSciences' Retained Earnings history runs 17 years deep, the most recent figure standing at -$196.4 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 119.18% year-over-year to -$196.4 million in Q1 2026; TTM through Mar 2026 was -$196.4 million, a 119.18% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 310285.71% from the prior year.
• Retained Earnings declined to -$196.4 million in Q1 2026 per PCRX's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $1.1 billion in Q4 2025 and bottomed at -$201.0 million in Q3 2025.
• The 5-year median for Retained Earnings is $105000.0 (2024), against an average of $250.6 million.
• Across the five-year window, Retained Earnings soared 722567.15% in 2024 and tumbled 29739.97% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$380000.0 in 2022, then jumped by 257108.68% to $976.6 million in 2023, then sank by 99.96% to $343000.0 in 2024, then jumped by 310285.71% to $1.1 billion in 2025, then tumbled by 118.45% to -$196.4 million in 2026.
• Per Business Quant, the three latest PCRX Retained Earnings figures stand at -$196.4 million (Q1 2026), $1.1 billion (Q4 2025), and -$201.0 million (Q3 2025).